Meeder Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-30
Closed -$5.48K 901
2025
Q4
$5.48K Buy
30
+2
+7% +$279 ﹤0.01% 783
2025
Q3
$3.4K Buy
+28
New +$3.15K ﹤0.01% 730
2025
Q2
Sell
-14
Closed -$1.63K 864
2025
Q1
$1.63K Buy
+14
New +$1.59K ﹤0.01% 878
2024
Q3
Sell
-47
Closed -$3.78K 845
2024
Q2
$3.78K Buy
+47
New +$3.48K ﹤0.01% 806
2020
Q4
Sell
-1,504
Closed -$108K 1884
2020
Q3
$108K Sell
1,504
-307
-17% -$23.9K 0.01% 763
2020
Q2
$149K Buy
1,811
+253
+16% +$19.5K 0.01% 661
2020
Q1
$92K Buy
1,558
+134
+9% +$10.9K 0.01% 733
2019
Q4
$147K Buy
1,424
+637
+81% +$25.7K 0.01% 687
2019
Q3
$17K Buy
+787
New +$20.2K ﹤0.01% 1361
2019
Q2
Sell
-146
Closed -$2K 2031
2019
Q1
$2K Sell
146
-2,387
-94% -$22.2K ﹤0.01% 1538
2018
Q4
$7K Sell
2,533
-1,501
-37% -$4.94K ﹤0.01% 1327
2018
Q3
$14K Buy
4,034
+2,796
+226% +$8.29K ﹤0.01% 1092
2018
Q2
$3.96K Buy
1,238
+43
+4% +$133 ﹤0.01% 1319
2018
Q1
$3K Sell
1,195
-159
-12% -$476 ﹤0.01% 1314
2017
Q4
$8K Buy
1,354
+519
+62% +$2.62K ﹤0.01% 1179
2017
Q3
$5K Buy
835
+310
+59% +$1.66K ﹤0.01% 1255
2017
Q2
$3K Hold
525
﹤0.01% 1311
2017
Q1
$2K Sell
525
-75
-13% -$358 ﹤0.01% 1347
2016
Q4
$4K Buy
+600
New +$4.21K ﹤0.01% 875

Other funds holding AXSM

Meeder Asset Management's AXSM Position: Q1 2026 in Review

Meeder Asset Management sold out of Axsome Therapeutics (AXSM) in Q1 2026, closing a stake of 30 shares — an estimated $5.48K sold.

Meeder Asset Management first reported a position in AXSM in Q4 2016 and held it in 19 quarters. The position peaked at $149K in Q2 2020. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Meeder Asset Management reported no remaining Axsome Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Meeder Asset Management sold 30 Axsome Therapeutics shares in Q1 2026, an estimated $5.48K.
  • Meeder Asset Management first reported a position in Axsome Therapeutics in Q4 2016 and held it in 19 quarters.
  • Meeder Asset Management's Axsome Therapeutics position peaked at $149K in Q2 2020.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Meeder Asset Management's 13F filing for Q1 2026, filed 7 May 2026.